• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $APLS

    Apellis Pharmaceuticals Inc.

    Subscribe to $APLS
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

    IPO Year: 2017

    Exchange: NASDAQ

    Website: apellis.com

    Peers

    $BCRX
    $ISEE
    $KZR
    $XERS

    Recent Analyst Ratings for Apellis Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    5/9/2025$23.00Buy → Neutral
    BofA Securities
    5/9/2025$52.00Strong Buy → Outperform
    Raymond James
    4/29/2025$44.00Overweight
    Cantor Fitzgerald
    12/17/2024$36.00Buy → Neutral
    Goldman
    11/21/2024$31.00Equal-Weight
    Morgan Stanley
    10/25/2024$25.00Sector Perform
    RBC Capital Mkts
    10/16/2024Sector Outperform
    Scotiabank
    10/16/2024Outperform
    William Blair
    5/31/2024$46.00Neutral
    Piper Sandler
    2/5/2024$68.00 → $80.00Hold → Buy
    Jefferies
    See more ratings

    Apellis Pharmaceuticals Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Apellis Pharmaceuticals Inc.

      10-Q - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

      5/7/25 7:01:36 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Apellis Pharmaceuticals Inc.

      DEFA14A - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

      4/23/25 7:35:44 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Apellis Pharmaceuticals Inc.

      DEF 14A - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

      4/23/25 7:33:44 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Apellis Pharmaceuticals Inc.

      8-K - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

      4/21/25 7:11:01 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Apellis Pharmaceuticals Inc.

      S-8 - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

      2/28/25 7:22:08 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Apellis Pharmaceuticals Inc.

      10-K - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)

      2/28/25 7:00:18 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Apellis Pharmaceuticals Inc.

      SCHEDULE 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      2/10/25 10:49:27 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Apellis Pharmaceuticals Inc.

      SCHEDULE 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      2/3/25 1:09:31 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Apellis Pharmaceuticals Inc.

      144 - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      1/29/25 3:42:05 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Apellis Pharmaceuticals Inc.

      144 - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      1/17/25 4:14:17 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Apellis Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

      Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million Increase in demand offset by inventory dynamics and funding shortages at co-pay assistance programs Received U.S. FDA filing acceptance of supplemental new drug application (sNDA) with Priority Review designation for EMPAVELI for treatment of C3G and primary IC-MPGNOn track to initiate two pivotal trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025Cash and cash equivalents of $358.4 million as of March 31, 2025;

      5/7/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

      WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will participate in the following May investor conferences: BofA Securities 2025 Healthcare Conference: Fireside chat on Tuesday, May 13, 2025 at 8:40 a.m. PTStifel 2025 Virtual Ophthalmology Forum: Fireside chat on Tuesday, May 27, 2025 at 2:30 p.m. ET The live conference webcasts will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcasts will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical compan

      5/6/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

      WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines co

      4/30/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Announces Craig Wheeler to Join the Board of Directors

      WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry. "We are thrilled to welcome Craig to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Craig is a seasoned leader, who has successfully grown biopharmaceutical companies into strong commercial organizations with robust pipelines

      4/21/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

      PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application (sNDA) for EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases. The Prescription Drug User Fee Act (PDUFA) target action date is July 28, 2025. "EMPAVELI demonstrated clinically meaningful benefits across all three key markers of disease – unprecedented proteinuria reducti

      4/1/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

      Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product revenue of $611.9 millionEMPAVELI® (pegcetacoplan) full year 2024 net product revenue of $98.1 million Submitted a supplemental new drug application (sNDA) for approval of EMPAVELI for C3G and primary IC-MPGN; U.S. launch anticipated in 2H 2025, if approved On track to initiate two Phase 3 trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025Cash and cash equivalents of $411.3 million as of December 31, 2024; projected revenues and cash expected to be sufficient to fund operations to p

      2/28/25 7:05:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

      WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. The live conference webcast will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients

      2/24/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

      WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) and Sobi® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments. "C3G and IC-MPGN are severe and life-threatening kidney conditions, often leading to kidney failure and requiring a kidney transplant or dialysis for life," said Lydia Abad-Franch, M.D., head of R&D and medical affairs and chief medi

      2/20/25 2:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

      WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company

      2/14/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Apellis Pharmaceuticals Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for EMPAVELI issued to APELLIS PHARMACEUTICALS INC

      Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity

      5/17/21 11:09:40 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Apellis Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

      Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million Increase in demand offset by inventory dynamics and funding shortages at co-pay assistance programs Received U.S. FDA filing acceptance of supplemental new drug application (sNDA) with Priority Review designation for EMPAVELI for treatment of C3G and primary IC-MPGNOn track to initiate two pivotal trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025Cash and cash equivalents of $358.4 million as of March 31, 2025;

      5/7/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

      WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines co

      4/30/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

      Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product revenue of $611.9 millionEMPAVELI® (pegcetacoplan) full year 2024 net product revenue of $98.1 million Submitted a supplemental new drug application (sNDA) for approval of EMPAVELI for C3G and primary IC-MPGN; U.S. launch anticipated in 2H 2025, if approved On track to initiate two Phase 3 trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and in delayed graft function (DGF) in 2H 2025Cash and cash equivalents of $411.3 million as of December 31, 2024; projected revenues and cash expected to be sufficient to fund operations to p

      2/28/25 7:05:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

      WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company

      2/14/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

      Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue of $152.0 million Increase in demand offset by higher gross-to-net adjustments in the quarter Following FDA feedback, on track to file an sNDA seeking approval of pegcetacoplan for C3G / primary IC-MPGN in early 2025 based on positive 6-month Phase 3 VALIANT results Cash and cash equivalents of $396.9 million as of September 30, 2024; projected revenues and cash expected to be sufficient to fund operations to positive cash flow Management to host conference call today at 8:30 a.m. ET

      11/5/24 7:05:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

      WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2024 financial results on Tuesday, November 5, 2024, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines

      10/22/24 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

      Met the primary endpoint, achieving statistically significant 68% (p<0.0001) reduction in proteinuria compared to placebo in a broad study populationPositive results consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneysDemonstrated favorable safety, consistent with established profileCompanies plan to submit data for regulatory approval in the US and EU Apellis to host a conference call today at 8:00 a.m. ET WALTHAM, Mass. and STOCKHOLM, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) and Sobi® (STO: SOBI) today announced positive topline results from the Phase 3 VALIANT study investi

      8/8/24 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

      Generated $199.7 million in 2Q 2024 revenues, including $179.1 million in U.S. net product sales $154.6 million for SYFOVRE® (pegcetacoplan injection) $24.5 million for EMPAVELI® (pegcetacoplan) Initiated a re-examination of the marketing authorization application of SYFOVRE with the European Medicines Agency (EMA); expect a final decision in 4Q 2024 Plan to report topline Phase 3 data with systemic pegcetacoplan in C3G / IC-MPGN in August 2024Cash and cash equivalents of $360.1 million as of June 30, 2024; projected revenues and cash expected to be sufficient to fund operations to positive cash flow Management to host conference call today at 8:30 a.m. ET WALTHAM, Mass., Aug. 01, 2024 (

      8/1/24 7:05:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

      WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2024 financial results on Thursday, August 1, 2024, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines

      7/18/24 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

      Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) Anticipates CHMP opinion for pegcetacoplan in GA no later than July 2024On track to report topline Phase 3 data with systemic pegcetacoplan in C3G / IC-MPGN in mid-2024Cash and cash equivalents of $325.9 million as of March 31, 2024; projected revenues and cash expected to be sufficient to fund operations for foreseeable futureManagement to host conference call today at 8:30 a.m. ET WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), today announced its f

      5/7/24 7:05:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Apellis Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

      SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      11/22/24 4:16:13 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

      SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      11/22/24 8:47:59 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

      SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      11/14/24 1:28:32 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

      SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      11/8/24 10:52:39 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      2/14/24 5:18:19 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

      SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      2/14/24 10:04:39 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      2/14/24 9:23:54 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      2/13/24 4:58:53 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      2/8/24 10:05:28 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

      9/8/23 10:29:34 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Apellis Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wheeler Craig A was granted 16,483 shares (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      4/21/25 4:23:01 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Wheeler Craig A

      3 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      4/21/25 4:09:13 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP/Chief Accounting Officer Chopas James George sold $4,543 worth of shares (183 units at $24.82), decreasing direct ownership by 0.38% to 47,955 units (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      3/18/25 12:27:02 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Watson David O. sold $139,789 worth of shares (5,569 units at $25.10), gifted 6,667 shares and received a gift of 6,667 shares, decreasing direct ownership by 4% to 138,730 units (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      3/6/25 5:17:05 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Business & Strat Officer Delong Mark Jeffrey sold $10,360 worth of shares (363 units at $28.54), decreasing direct ownership by 0.43% to 83,945 units (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      2/12/25 1:59:21 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Watson David O. sold $20,519 worth of shares (695 units at $29.52), decreasing direct ownership by 0.48% to 144,299 units (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      1/30/25 12:20:07 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Townsend Adam J. sold $20,519 worth of shares (695 units at $29.52), decreasing direct ownership by 0.82% to 84,050 units (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      1/30/25 12:18:22 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Sullivan Timothy Eugene sold $16,120 worth of shares (546 units at $29.52), decreasing direct ownership by 0.42% to 128,665 units (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      1/30/25 12:15:46 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Technical Officer Nicholson Nur sold $24,357 worth of shares (825 units at $29.52), decreasing direct ownership by 0.98% to 83,664 units (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      1/30/25 12:13:56 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief People Officer Lewis Karen sold $10,747 worth of shares (364 units at $29.52), decreasing direct ownership by 0.52% to 70,251 units (SEC Form 4)

      4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

      1/30/25 12:12:03 PM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Apellis Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Apellis Pharmaceuticals downgraded by Raymond James with a new price target

      Raymond James downgraded Apellis Pharmaceuticals from Strong Buy to Outperform and set a new price target of $52.00

      5/9/25 8:40:54 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals downgraded by BofA Securities with a new price target

      BofA Securities downgraded Apellis Pharmaceuticals from Buy to Neutral and set a new price target of $23.00

      5/9/25 8:40:54 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Apellis Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Apellis Pharmaceuticals with a rating of Overweight and set a new price target of $44.00

      4/29/25 8:10:45 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals downgraded by Goldman with a new price target

      Goldman downgraded Apellis Pharmaceuticals from Buy to Neutral and set a new price target of $36.00

      12/17/24 7:26:36 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Apellis Pharmaceuticals with a new price target

      Morgan Stanley initiated coverage of Apellis Pharmaceuticals with a rating of Equal-Weight and set a new price target of $31.00

      11/21/24 7:28:02 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Apellis Pharmaceuticals with a new price target

      RBC Capital Mkts initiated coverage of Apellis Pharmaceuticals with a rating of Sector Perform and set a new price target of $25.00

      10/25/24 7:29:41 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Apellis Pharmaceuticals

      Scotiabank initiated coverage of Apellis Pharmaceuticals with a rating of Sector Outperform

      10/16/24 8:38:45 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Apellis Pharmaceuticals

      William Blair initiated coverage of Apellis Pharmaceuticals with a rating of Outperform

      10/16/24 7:13:18 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Apellis Pharmaceuticals with a new price target

      Piper Sandler initiated coverage of Apellis Pharmaceuticals with a rating of Neutral and set a new price target of $46.00

      5/31/24 7:35:45 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Pharmaceuticals upgraded by Jefferies with a new price target

      Jefferies upgraded Apellis Pharmaceuticals from Hold to Buy and set a new price target of $80.00 from $68.00 previously

      2/5/24 6:30:09 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Apellis Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Apellis Announces Craig Wheeler to Join the Board of Directors

      WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry. "We are thrilled to welcome Craig to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Craig is a seasoned leader, who has successfully grown biopharmaceutical companies into strong commercial organizations with robust pipelines

      4/21/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Apellis Announces Keli Walbert to Join the Board of Directors

      WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical commercial leadership experience to the Board. "We are delighted to welcome Keli to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Keli has a proven track record of successfully bringing novel medicines to patients as well as a respected reputation among industry leaders for her strategic thinking and innovation. Her deep commercial expertise will be invaluable as we c

      1/10/25 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

      WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18. "Phil is globally renowned for his leadership in retina, including as a past president of the American Society of Retina Specialists (ASRS), so we are delighted to welcome him to the Apellis team," said Caroline Baumal, M.D., Chief Medical Officer, Apellis. "Phil has extensive expertise in retina research and patient care, which will be invaluable as we continue to bring SYFOVRE to patients with GA and advance our retina pipeline." "It is an honor to jo

      3/11/24 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

      WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer. Dr. Baumal replaces Federico Grossi, M.D., Ph.D., who plans to remain at Apellis until February 28, 2023 to help with the transition and preparations for the potential launch of pegcetacoplan for geographic atrophy (GA). "Caroline is a world-renowned retina specialist who has been at the forefront of retina research and patient care for over 25 years, and we are thrilled to welcome her to Apellis," said Cedric Francois, M.

      1/5/23 7:00:00 AM ET
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board

      Cognito Therapeutics, a Phase 3-ready disease-modifying digital therapeutics company, today announced the appointment of Gerald Chan, ScD. as Chairman of the Board. Cognito is a pioneer in using neuromodulation to engage novel targets of neuronal pathophysiology to achieve disease modification in neurodegenerative diseases. Dr. Chan is the co-founder of Morningside, a privately held venture capital and private equity firm. Since inception, Morningside has focused on the development and commercialization of novel scientific discoveries in both the life sciences and technology sectors. "The use of non-pharmacological interventions to treat neurocognitive decline represents a fundamental shif

      7/6/21 8:00:00 AM ET
      $MITO
      $APLS
      Biotechnology: Pharmaceutical Preparations
      Health Care